<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210513051283N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-15</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the expanded conjunctiva in pterygium surgery</public_title>
      <acronym></acronym>
      <scientific_title>Pterygium surgery by using autologous conjunctival cells transplantation implanted on human amniotic membrane</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56351</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>primary pterygium-.</hc_freetext>
      <i_freetext>Intervention group: We will get a sample of conjuctiva, 2x1 mm, from inferior fornix of the eye with pterygium two weeks before operation. After isolation the epithelium from tenon layer, the sample will be sent to laboratory. In laboratory this sample will be chopped and implanted over amniotic membrane (epithelial side). Then, this complex will be put in an acellular culture media, keratonocyte growth media, that consists of 10 ng/ml human epidermal growth factor (Gibco) ،5 _g/ml insulin (Sigma) ،0.5 _g/ml hydrocortisone (Sigma) 30 _g/ml bovine pituitary extract (Sigma) ،50 _g/ml Gentamicin (Gibco) ،50 ng/ml Amphotericin B (Gibco). Calcium concentration is 15/0 Millimol in culture media. Adhesion and proliferation of cells will increase by increasing the calcium concentration to 9/0 Mm. The chopped sample and 500 micro- liters culture media will have cultured in an incubator of 37 centigrade temperature, 5/5 % Co2 and 95% humidity for one to two weeks. the culture media will change every two to three days and at each change cells will evaluate by microscope. we will use of more amount of culture media by adhesion the cells to amniotic membrane. We evaluate the cells  based on rate of cells growth and adhesion to amniotic membrane every day. In addition, cells growth is visible by color change of culture media. After ending the cultivation and proliferation of cells on amniotic membrane, the complex will put up in a new culture media that consists of Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F12 media (Gibco), supplemented with 2.5% fetal bovine serum (Hyclone, Logan, Utah), 10 ng/ml human epidermal growth factor, 5 _g/ml insulin, 0.4 _g/ml hydrocortisone, 8.4 ng/ml cholera toxin (Sigma), 50 _g/ml streptomycin (Gibco), and 50 IU/ml penicillin (Gibco) for three days..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Aghaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rassoul Akram Hospital, Niyayesh avenue satarkhan street Tehran Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6650 9162</telephone>
        <email>aghaei.h@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Aghaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rassoul Akram Hospital, Niyayesh avenue Sattarkhan street Tehran Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6650 9162</telephone>
        <email>aghaei.h@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>presence the primary pterygium</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>ِDissatisfaction patients</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H11.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pterygium of eye</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: We will get a sample of conjuctiva, 2x1 mm, from inferior fornix of the eye with pterygium two weeks before operation. After isolation the epithelium from tenon layer, the sample will be sent to laboratory. In laboratory this sample will be chopped and implanted over amniotic membrane (epithelial side). Then, this complex will be put in an acellular culture media, keratonocyte growth media, that consists of 10 ng/ml human epidermal growth factor (Gibco) ،5 _g/ml insulin (Sigma) ،0.5 _g/ml hydrocortisone (Sigma) 30 _g/ml bovine pituitary extract (Sigma) ،50 _g/ml Gentamicin (Gibco) ،50 ng/ml Amphotericin B (Gibco). Calcium concentration is 15/0 Millimol in culture media. Adhesion and proliferation of cells will increase by increasing the calcium concentration to 9/0 Mm. The chopped sample and 500 micro- liters culture media will have cultured in an incubator of 37 centigrade temperature, 5/5 % Co2 and 95% humidity for one to two weeks. the culture media will change every two to three days and at each change cells will evaluate by microscope. we will use of more amount of culture media by adhesion the cells to amniotic membrane. We evaluate the cells  based on rate of cells growth and adhesion to amniotic membrane every day. In addition, cells growth is visible by color change of culture media. After ending the cultivation and proliferation of cells on amniotic membrane, the complex will put up in a new culture media that consists of Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F12 media (Gibco), supplemented with 2.5% fetal bovine serum (Hyclone, Logan, Utah), 10 ng/ml human epidermal growth factor, 5 _g/ml insulin, 0.4 _g/ml hydrocortisone, 8.4 ng/ml cholera toxin (Sigma), 50 _g/ml streptomycin (Gibco), and 50 IU/ml penicillin (Gibco) for three days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Evaluation of re-epithelialization of cultivated  tissue. Timepoint: Before conjunctival transplantation. Method of measurement: Hematoxilin-eosin staining.</prim_outcome>
      <prim_outcome>Evaluation of collagenesis. Timepoint: Before conjunctival transplantation. Method of measurement: Trichrome-mason staining.</prim_outcome>
      <prim_outcome>Evaluation of re-epithelialization and collagenesis of cultivated tissue. Timepoint: Before conjunctival transplantation. Method of measurement: Expression of integrin B 1,MUC4,CX43,Oct4,p63,CK19,CK13,CK12,CK3 by RT-PCR.</prim_outcome>
      <prim_outcome>Healing process of transplanted conjunctiva. Timepoint: Day 1,3,7 and months 1,3,6,12. Method of measurement: Examination and Fluorescin staining.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-20</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Hemmat Highway near to Milad Tower Iran University of medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
